N/A N=58 Voice Therapy With a Semi-occluded Vocal Tract
Voice Disorders
Primary: (Supra)Glottic Activity: Amplitude of Vibration — 37.7; 32.5; 28.8; 37.1 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Cancer
Glottic Carcinoma
Primary: Number of Patients With Local Failure Following SABR Treatment of Early Glottic Larynx Cancers — 2 participants
Phase 4 N=60 Comparing Hemodynamic Changes for Intubation With Shikani Intubating Stylet and Macintosh Laryngoscope
Anesthesia
Primary: Heart Rate and Blood Pressure Double Product — 9114; 8804 (beats/minute)*mmHg
N/A N=50 Glottic View Using Supraglottic Devices in Pediatric Patients
Operative Surgical Procedures
Primary: Acceptable View of the Glottic Aperature (Grade I-II) — 20; 21 participants
Phase 2 N=37 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Phase 2 N=54 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Biliary Tract Neoplasms · Liver Cancer · Hepatocellular Carcinoma
Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months
Phase 2 N=39 Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Neuroendocrine Carcinoma
Primary: Net Change Relative to Baseline in Tumor Blood Flow — -0.44; -0.12; -0.60; -0.40 ml/min/100gm
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 2 N=30 Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
Renal Cell Carcinoma
Primary: Progression-free Survival — 8.3 months
Phase 2 N=72 Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma · Neoplasm Metastases
Primary: To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy. — 25…
Phase 2 N=20 UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
Advanced Solid Tumors · Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 300 mg
Phase 1 N=12 Phase Ib of L-NMMA and Pembrolizumab
Non-Small Cell Lung Cancer · Malignant Melanoma · Head and Neck Squamous Cell Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/kg
Phase 4 N=50 Comparison of Storz C-MAC and D-MAC Orotracheal Intubation Systems in Morbidly Obese Patients
Obesity
Primary: Time for Intubation — 9; 7.3 seconds
N/A N=50 Comparison of I-gel to the Laryngeal Mask Airway
Endotracheal Intubation · Supraglottic Airway
Primary: Time Required for Intubation — 21.04; 30.04 seconds — p=0.02
N/A N=8 Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation
Essential Tremor
Primary: Vocal Tremor Scoring System (VTSS) — 0.57; 0.57; 1; 0.43 units on a scale